Comparative Pharmacology
Head-to-head clinical analysis: MD 60 versus MD 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 60 versus MD 76.
MD-60 vs MD-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-60 is a nonionic iodinated contrast agent. It attenuates X-rays by increasing the density of structures and organs, improving radiographic visualization.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Intravenous administration, 60 mg/kg as a single dose over 30 min.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in patients with normal renal function (CrCl >90 mL/min); prolonged to >40 hours in moderate renal impairment (CrCl 30–60 mL/min), requiring dose adjustment.
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Primarily renal elimination of unchanged drug (~60% within 24 hours) via glomerular filtration; biliary/fecal excretion accounts for ~30% as metabolites; ~10% undergoes enterohepatic recirculation.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent